Jubilant Cadista Pharmaceuticals Inc. discovers, develops, manufactures, and distributes prescription generic pharmaceutical products to customers in the United States. It offers anti-hypertensive, diuretic, and andrenocortical steroid tablets and capsules. The company’s generic products include alendronate sodium, cyclobenzaprine HCL, donepezil, escitalopram, hydrochlorothiazide, lamotrigine, losartan HCTZ, losartan potassium, meclizine, methylprednisolone, olanzapine ODT, oxcarbazepine, pantoprazole delayed release, prednisone, prochlorperazine maleate, risperidone odt, terazosin HCL, and valacyclovir. Jubilant Cadista Pharmaceuticals Inc. was formerly known as Cadista Pharmaceuticals, Inc...
207 Kiley Drive
Salisbury, MD 21801
Founded in 1991
Cadista Holdings Inc. and Jubilant Cadista Pharmaceuticals Inc. Announce Resignation of Neeraj Agrawal from their Board of Directors
Aug 5 14
Cadista Holdings Inc. announced that by letter, dated August 1, 2014, Neeraj Agrawal resigned as a member of the company's Board of Directors, and as a member of the Board of Directors of its wholly-owned subsidiary, Jubilant Cadista Pharmaceuticals Inc., in each case effective immediately following the Board of Directors meetings held on such date.
Cadista Holdings Inc. and Jubilant Cadista Pharmaceuticals Inc. Elects R. Sankaraiah to as Director of Both Companies
Aug 6 13
On July 31, 2013 the Board of Directors of Cadista Holdings Inc. and the Company's Jubilant Cadista Pharmaceuticals Inc. elected R. Sankaraiah to serve as a director of each of the Company and Cadista Pharmaceuticals. Mr. Sankaraiah, in addition to being a member of the Board of Directors, will also serve as a member of the Audit Committee of the Company and has been designated by the Board as a "financial expert" in accordance with applicable SEC regulations. Mr. Sankaraiah was previously a director of the Company and Cadista Pharmaceuticals from June 2005 until his resignation on May 4, 2012. From the time of the formation of the Company's Audit Committee in May 2011 until his resignation in May 2012, Mr. Sankaraiah was also on the Company's Audit Committee and was designated by the Board as a 'financial expert' in accordance with applicable SEC regulations.